$0.07 Earnings Per Share Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter

Wall Street brokerages predict that NeoGenomics, Inc. (NASDAQ:NEO) will announce $0.07 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for NeoGenomics’ earnings, with estimates ranging from $0.05 to $0.09. NeoGenomics reported earnings of $0.06 per share in the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 18th.

According to Zacks, analysts expect that NeoGenomics will report full year earnings of $0.28 per share for the current year, with EPS estimates ranging from $0.26 to $0.30. For the next year, analysts expect that the company will report earnings of $0.37 per share, with EPS estimates ranging from $0.33 to $0.42. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover NeoGenomics.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, October 29th. The medical research company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The company had revenue of $104.70 million during the quarter, compared to analyst estimates of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. NeoGenomics’s quarterly revenue was up 51.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 EPS.

A number of research firms have commented on NEO. BidaskClub upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research note on Friday, December 13th. ValuEngine lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a research note on Tuesday, October 29th. Needham & Company LLC initiated coverage on shares of NeoGenomics in a research report on Friday, January 3rd. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $22.50.

In other news, CAO Kathryn B. Mckenzie sold 8,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $26.37, for a total transaction of $210,960.00. Following the transaction, the chief accounting officer now owns 10,273 shares in the company, valued at approximately $270,899.01. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider George Cardoza sold 51,556 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.82, for a total transaction of $1,176,507.92. Following the sale, the insider now directly owns 356,387 shares of the company’s stock, valued at $8,132,751.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 471,874 shares of company stock valued at $11,259,917. Company insiders own 8.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in NEO. Nisa Investment Advisors LLC boosted its stake in NeoGenomics by 867.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock worth $74,000 after acquiring an additional 3,470 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in NeoGenomics by 75.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock worth $87,000 after purchasing an additional 1,950 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in NeoGenomics by 14.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock worth $110,000 after purchasing an additional 739 shares during the period. NumerixS Investment Technologies Inc bought a new stake in shares of NeoGenomics in the second quarter valued at about $169,000. Finally, Sigma Planning Corp bought a new stake in shares of NeoGenomics in the third quarter valued at about $201,000. Institutional investors own 83.28% of the company’s stock.

NEO traded down $0.61 during trading hours on Friday, reaching $31.99. The company’s stock had a trading volume of 175,626 shares, compared to its average volume of 905,314. NeoGenomics has a fifty-two week low of $15.15 and a fifty-two week high of $33.21. The stock has a market cap of $3.40 billion, a PE ratio of 246.11 and a beta of 1.06. The business’s 50-day moving average is $28.32 and its 200-day moving average is $24.21. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.24 and a quick ratio of 4.05.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Recommended Story: S&P 500 Index

Get a free copy of the Zacks research report on NeoGenomics (NEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.